RIC Leadership

The REMS Industry Consortium is led by a Board of Directors representing the six founding companies. These are forward-looking organizations committed to coalescing the REMS professional community in the service of patient safety and REMS innovation. 

RIC Board of Directors

Kevin Holman, RIC Board Member & Chairperson

Kevin Holman, MBA, RAC, RIC Board Member & Chairperson
The Janssen Pharmaceutical Companies of Johnson & Johnson

Kevin Holman, MBA, RAC leads the REMS & Risk Management Center of Excellence at Janssen Pharmaceuticals where he built and leads a team of risk management experts to oversee the design, implementation, management, and assessment of risk management programs in the U.S. and North America. Throughout his career, Kevin has contributed to nearly half of the currently-approved shared REMS programs and dozens of single-product REMS programs across various therapeutic areas. Kevin holds a Master of Business Administration degree from Webster University, a Bachelor of Science degree in Biological Sciences from Southern Illinois University ‒ Edwardsville, and a Regulatory Affairs Certification (US-RAC) from the Regulatory Affairs Professional Society.

Sherice Mills, RIC Board Member & Vice Chairperson

Sherice Mills, RIC Board Member & Vice Chairperson
Jazz Pharmaceuticals

Sherice Mills has had the opportunity to work on many of the industry’s shared REMS programs in place today. She is Executive Director and currently leads the Risk Management U.S. and Canada (RMUS&C) group at Jazz Pharmaceuticals. Sherice has worked in the REMS space since its inception in 2007 and has an expansive involvement with the development and implementation of both single and shared REMS systems and operations. She has engaged with the FDA for REMS programs many times throughout the years. Managing one of the more complex programs in operation today has provided her numerous opportunities to address different nuances and unique facets of REMS that not all programs will experience. As an alumni of the Saint Louis Business Diversity Leadership Initiative, she participates in activities that endeavor to provide mentorship and guidance to those looking to enhance their understanding of various aspects of science and both professional and personal development. Sherice obtained her Bachelor of Science in Biology/Chemistry from Maryville University, St. Louis, Missouri.

Kishore Gopu, RIC Board Member & Secretary

Kishore Gopu, MS, MBA, RIC Board Member & Secretary
Teva Pharmaceuticals

Kishore Gopu, M.S., MBA, Senior Director, REMS Operations has been with Teva since 2007 and has served in many departments including Regulatory Affairs, Commercial Operations, Patient Solutions, Market Access, and Pharmacovigilance. Since joining Teva, Kishore has built the REMS department from the ground up and has been leading it for the last nine years. Prior to Teva, he worked/consulted for many large corporations, including Wyeth and Johnson & Johnson, for six years. He was involved in the development and implementation of over a half dozen shared REMS programs including the iPLEDGE®, TIRF REMS, Opioid REMS, and Clozapine REMS to name a few, and continues to be responsible for the oversight of Teva’s REMS portfolio. Kishore holds a M.S. from the University of South Carolina and a MBA from Fairleigh Dickinson University.

Kal Elhoregy, RPh, PA, RIC Board Member & Treasurer

Kal Elhoregy, RPh, PA, RIC Board Member & Treasurer
Amneal Pharmaceuticals

Kal Elhoregy, R. PH, PA, is an accomplished healthcare industry executive with 25+ years’ experience focused on implementation of Risk Minimization Programs, Quality Management Systems, Pharmacovigilance Compliance, Quality Risk Management, Audits and Inspection Readiness for companies within the pharmaceutical industry. In his current role as a Director, Risk Evaluation and Mitigation Strategy (REMS), Regulatory Affairs Clinical at Amneal Pharmaceuticals, he manages all REMS activities for multiple programs including operations and development of new programs and ensures the entity’s full compliance with the regulatory requirement and risk management standards and guidelines. Kal received his Bachelor of Science, Accounting from the Faculty of Commerce, Ain Shams University and his Bachelor of Science of Pharmacy from Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY.

Michael Cheung, DHSc, MS, RIC Board Member
Bristol-Myers Squibb

Michael Cheung, DHSc, MS is currently the Senior Director of REMS Strategy and Submissions at Bristol Myers Squibb where he leads a team focused on establishing the U.S. elements of the company's risk management strategies to support their expanding and evolving portfolio. With over 19 years of biopharmaceutical industry experience spanning risk management, pharmacovigilance, medical affairs, and clinical research roles, Michael leans on his broad experience to ensure patient safety. Michael holds a Doctor of Health Sciences degree from A.T. Still University, a Master's degree in Regulatory Affairs from Northeastern University, and a Bachelor's degree in Kinesiology from San Diego State University.

Jennifer Church, RIC Board Member

Jennifer Church, RN, BSN, RIC Board Member

Jennifer Church, RN, BSN, is a Registered Nurse by profession and spent over eleven years focusing on Newborn Intensive Care. In 2001, she transitioned to a Utilization Review role at Viatris, and beginning in 2006, she began developing her extensive background in pharmacovigilance and drug safety. She continues at Viatris and is Manager, REMS Safety. Jennifer has been a single point of contact for multiple REMS programs beginning in 2017 and currently maintains oversight of all of Viatris’ US and Canada Risk Management Programs. Jennifer earned her Bachelor of Science degree in Nursing from West Virginia University.